Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art

Bibliography

• Hallschmid M, Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 2009;52:2264-9
   PubMed Web of Science ®Google Scholar
• Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimer's Dis 2005;8:247-68
   PubMed Web of Science ®Google Scholar
• Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimer's Dis 2005;7:63-80
   PubMed Web of Science ®Google Scholar
• de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009;42:475-81
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Longato L, Tong M, et al. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 2009;10:1049-60
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Tong M, Wands JR. Insulin resistance, cognitive impairment, and neurodegeneration: roles of nitrosamine exposure, diet, and lifestyles. In: de la Monte SM, editor. Alzheimer‘s disease pathogenesis-core concepts, shifting paradigms and therapeutic Targets. InTech, Rijeka, Croatia; 2011. p. 459-96
   Google Scholar
• de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012;72:49-66
   PubMed Web of Science ®Google Scholar
• Derakhshan F, Toth C. Insulin and the brain. Curr Diabetes Rev 2013;9:102-16
   PubMedGoogle Scholar
• de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimer's Dis 2005;7:45-61
   PubMed Web of Science ®Google Scholar
• Xu J, Yeon JE, Chang H, et al. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem 2003;278:26929-37
   PubMed Web of Science ®Google Scholar
• Soscia SJ, Tong M, Xu XJ, et al. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell Mol Life Sci 2006;63:2039-56
   PubMed Web of Science ®Google Scholar
• Benedict C, Hallschmid M, Schultes B, et al. Intranasal insulin to improve memory function in humans. Neuroendocrinology 2007;86:136-42
   PubMed Web of Science ®Google Scholar
• Freiherr J, Hallschmid M, Frey WH II, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013;27:505-14
   PubMed Web of Science ®Google Scholar
• Henkin RI. Intranasal insulin: from nose to brain. Nutrition 2010;26:624-33
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Takeda M. Expression of insulin-like growth factor family in the rat olfactory epithelium. Anat Embryol (Berl) 2002;205:401-5
   PubMedGoogle Scholar
• Ferguson MW, Sharpe PM, Thomas BL, et al. Differential expression of insulin-like growth factors I and II (IGF I and II), mRNA, peptide and binding protein 1 during mouse palate development: comparison with TGF beta peptide distribution. J Anat 1992;181(Pt 2):219-38
   PubMedGoogle Scholar
• Lester-Coll N, Rivera EJ, Soscia SJ, et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimer's Dis 2006;9:13-33
   PubMed Web of Science ®Google Scholar
• Moroz N, Tong M, Longato L, et al. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimer's Dis 2008;15:29-44
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Wands JR. Insulin resistance and neurodegeneration: type 2 versus Type 3 diabetes mellitus. Emerg Drugs Targets AD 2009;1:235-54
   Google Scholar
• Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-38
   PubMed Web of Science ®Google Scholar
• Sun X, Yao H, Douglas RM, et al. Insulin/PI3K signaling protects dentate neurons from oxygen-glucose deprivation in organotypic slice cultures. J Neurochem 2010;112:377-88
   PubMed Web of Science ®Google Scholar
• McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630:158-62
   PubMed Web of Science ®Google Scholar
• Scherer T, Lehnert H, Hallschmid M. Brain insulin and leptin signaling in metabolic control: from animal research to clinical application. Endocrinol Metab Clin North Am 2013;42:109-25
   PubMed Web of Science ®Google Scholar
• Wada A, Yokoo H, Yanagita T, et al. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics. J Pharmacol Sci 2005;99:128-43
   PubMed Web of Science ®Google Scholar
• Ketterer C, Tschritter O, Preissl H, et al. Insulin sensitivity of the human brain. Diabetes Res Clin Pract 2011;93(Suppl 1):S47-51
   PubMedGoogle Scholar
• Schioth HB, Frey WH, Brooks SJ, et al. Insulin to treat Alzheimer's disease: just follow your nose? Expert Rev Clin Pharmacol 2012;5:17-20
   PubMed Web of Science ®Google Scholar
• Molina JA, Jimenez-Jimenez FJ, Vargas C, et al. Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. Acta Neurol Scand 2002;106:347-50
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Sasaki K, Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 1991;30:1219-28
   PubMed Web of Science ®Google Scholar
• Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164-8
   PubMed Web of Science ®Google Scholar
• de la Monte SM. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimer's Dis 2012;30:S231-49
   PubMed Web of Science ®Google Scholar
• de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012;9:35-66
   PubMed Web of Science ®Google Scholar
• de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) 2012;4:1582-605
   PubMedGoogle Scholar
• de la Monte SM. Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin resistance diseases. Panminerva Med 2012;54:171-8
   PubMed Web of Science ®Google Scholar
• Hoyer S, Muller D, Plaschke K. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm Suppl 1994;44:259-68
   PubMedGoogle Scholar
• Hoyer S, Lannert H, Noldner M, et al. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 1999;106:1171-88
   PubMed Web of Science ®Google Scholar
• Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003;23:7084-92
   PubMed Web of Science ®Google Scholar
• Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004;101:3100-5
   Google Scholar
• de la Monte SM, Tong M, Bowling N, et al. si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Mol Brain 2011;4:13
   PubMedGoogle Scholar
• Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 2002;109:341-60
   PubMed Web of Science ®Google Scholar
• Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012;122:1339-53
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Tong M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimer's Dis 2006;10:89-109
   PubMed Web of Science ®Google Scholar
• Laron Z. Insulin and the brain. Arch Physiol Biochem 2009;115:112-16
   PubMedGoogle Scholar
• Morris JK, Burns JM. Insulin: an emerging treatment for Alzheimer's disease dementia? Curr Neurol Neurosci Rep 2012;12:520-7
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes: evidence reviewed. J Diabetes Sci Tech 2008;2:1101-13
   PubMedGoogle Scholar
• Jauch-Chara K, Friedrich A, Rezmer M, et al. Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes 2012;61:2261-8
   PubMed Web of Science ®Google Scholar
• Posey KA, Clegg DJ, Printz RL, et al. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 2009;296:E1003-12
   PubMed Web of Science ®Google Scholar
• Bohringer A, Schwabe L, Richter S, et al. Intranasal insulin attenuates the hypothalamic-pituitary-adrenal axis response to psychosocial stress. Psychoneuroendocrinology 2008;33:1394-400
   PubMed Web of Science ®Google Scholar
• Bale TL, Anderson KR, Roberts AJ, et al. Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 2003;144:2580-7
   PubMed Web of Science ®Google Scholar
• Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann NY Acad Sci 2006;1083:77-110
   PubMed Web of Science ®Google Scholar
• Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore longitudinal study of aging. JAMA Neurol 2013;70(9):1167-72
   Google Scholar
• Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med 2013;369:540-8
   PubMed Web of Science ®Google Scholar
• Baker LD, Cross DJ, Minoshima S, et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011;68:51-7
   PubMed Web of Science ®Google Scholar
• Dominguez RO, Marschoff ER, Gonzalez SE, et al. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res Clin Pract 2012;98:68-74
   PubMed Web of Science ®Google Scholar
• Henkin RI. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action. Nutrition 2010;26:33-9
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5
   PubMedGoogle Scholar
• Benedict C, Frey WH II, Schioth HB, et al. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011;46:112-15
   PubMed Web of Science ®Google Scholar
• Chapman CD, Frey WH II, Craft S, et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 2013;30(10):2475-84
   PubMed Web of Science ®Google Scholar
• Messier C, Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 2005;12:311-28
   PubMedGoogle Scholar
• Reger MA, Watson GS, Frey WH II, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27:451-8
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimer's Dis 2008;13:323-31
   PubMed Web of Science ®Google Scholar
• Ott V, Benedict C, Schultes B, et al. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012;14:214-21
   PubMed Web of Science ®Google Scholar
• Shemesh E, Rudich A, Harman-Boehm I, et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012;97:366-76
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440-8
   PubMed Web of Science ®Google Scholar
• Schioth HB, Craft S, Brooks SJ, et al. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol 2012;46:4-10
   PubMed Web of Science ®Google Scholar
• Hallschmid M, Benedict C, Schultes B, et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008;149:79-83
   PubMed Web of Science ®Google Scholar
• Ryan KK, Woods SC, Seeley RJ. Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity. Cell Metab 2012;15:137-49
   PubMed Web of Science ®Google Scholar
• Reagan LP. Insulin signaling effects on memory and mood. Curr Opin Pharmacol 2007;7:633-7
   PubMed Web of Science ®Google Scholar
• Hallschmid M, Benedict C, Schultes B, et al. Intranasal insulin reduces body fat in men but not in women. Diabetes 2004;53:3024-9
   PubMed Web of Science ®Google Scholar
• Guthoff M, Grichisch Y, Canova C, et al. Insulin modulates food-related activity in the central nervous system. J Clin Endocrinol Metab 2010;95:748-55
   PubMed Web of Science ®Google Scholar
• Guthoff M, Stingl KT, Tschritter O, et al. The insulin-mediated modulation of visually evoked magnetic fields is reduced in obese subjects. PLoS one 2011;6:e19482
   PubMedGoogle Scholar
• Hallschmid M, Benedict C, Schultes B, et al. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 2008;32:275-82
   PubMed Web of Science ®Google Scholar
• Heni M, Kullmann S, Ketterer C, et al. Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. Diabetologia 2012;55:1773-82
   PubMed Web of Science ®Google Scholar
• Benedict C, Kern W, Schultes B, et al. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 2008;93:1339-44
   PubMed Web of Science ®Google Scholar
• Krug R, Benedict C, Born J, et al. Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 2010;95:E468-72
   PubMed Web of Science ®Google Scholar
• Kullmann S, Frank S, Heni M, et al. Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women. Neuroendocrinology 2013;97:176-82
   PubMed Web of Science ®Google Scholar
• Francis GJ, Martinez JA, Liu WQ, et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008;131:3311-34
   PubMed Web of Science ®Google Scholar
• Bonifacio E, Achenbach P, Pan L, et al. Mucosal insulin vaccination for type 1 diabetes prevention. Exp Clin Endocrinol Diabetes 2008;116(Suppl 1):S26-9
   PubMedGoogle Scholar
• Nanto-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372:1746-55
   PubMed Web of Science ®Google Scholar
• Vig PJ, Subramony SH, D'Souza DR, et al. Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull 2006;69:573-9
   PubMed Web of Science ®Google Scholar
• Liu XF, Fawcett JR, Hanson LR, et al. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc 2004;13:16-23
   PubMedGoogle Scholar
• Lin S, Fan LW, Rhodes PG, et al. Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 2009;217:361-70
   PubMed Web of Science ®Google Scholar
• Kooijman R, Sarre S, Michotte Y, et al. Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke 2009;40:e83-8
   PubMed Web of Science ®Google Scholar
• Patel MM, Goyal BR, Bhadada SV, et al. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009;23:35-58
   PubMed Web of Science ®Google Scholar
• Reger MA, Craft S. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today (Barc) 2006;42:729-39
   PubMed Web of Science ®Google Scholar
• D'Souza R, Mutalik S, Venkatesh M, et al. Insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies. AAPS PharmSciTech 2005;6:E184-9
   PubMed Web of Science ®Google Scholar
• Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009;10:243-9
   PubMed Web of Science ®Google Scholar
• Sakuma S, Suita M, Masaoka Y, et al. Oligoarginine-linked polymers as a new class of penetration enhancers. J Control Release 2010;148:187-96
   PubMed Web of Science ®Google Scholar
• McInnes FJ, O'Mahony B, Lindsay B, et al. Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. Eur J Pharm Sci 2007;31:25-31
   PubMed Web of Science ®Google Scholar
• Chung SW, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics. J Drug Target 2012;20:481-501
   PubMed Web of Science ®Google Scholar
• Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci 2007;96:473-83
   PubMed Web of Science ®Google Scholar
• Arnold JJ, Fyrberg MD, Meezan E, et al. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-D-maltoside. J Pharm Sci 2010;99:1912-20
   PubMed Web of Science ®Google Scholar
• Duan X, Mao S. New strategies to improve the intranasal absorption of insulin. Drug Discov Today 2010;15:416-27
   PubMed Web of Science ®Google Scholar
• Stote R, Marbury T, Shi L, et al. Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Tech 2010;4:603-9
   PubMedGoogle Scholar
• Stote R, Miller M, Marbury T, et al. Enhanced absorption of Nasulin, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. J Diabetes Sci Tech 2011;5:113-19
   PubMedGoogle Scholar
• Krishnankutty RK, Mathew A, Sedimbi SK, et al. Alternative routes of insulin delivery. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009;34:933-48
   PubMedGoogle Scholar
• Leary AC, Stote RM, Breedt HJ, et al. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. Diabetes Technol Ther 2005;7:124-30
   PubMedGoogle Scholar
• Strachan MW. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem Soc Trans 2005;33:1037-40
   PubMed Web of Science ®Google Scholar
• Benedict C, Hallschmid M, Schmitz K, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2007;32:239-43
   PubMed Web of Science ®Google Scholar
• Benedict C, Dodt C, Hallschmid M, et al. Immediate but not long-term intranasal administration of insulin raises blood pressure in human beings. Metabolism 2005;54:1356-61
   PubMed Web of Science ®Google Scholar
• Hotta O, Taguma Y, Chiba S, et al. Possible relationship between hyperinsulinemia and glomerular hypertrophy in nephrosclerosis. Ren Fail 1996;18:271-8
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63:1187-92
   PubMed Web of Science ®Google Scholar
• Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005;62:1539-44
   PubMed Web of Science ®Google Scholar
• Neumann KF, Rojo L, Navarrete LP, et al. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res 2008;5:438-47
   PubMed Web of Science ®Google Scholar
• Roriz-Filho SJ, Sa-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009;1792:432-43
   PubMed Web of Science ®Google Scholar
• Lahousse SA, Carter JJ, Xu XJ, et al. Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol 2006;7:41
   PubMedGoogle Scholar
• Imfeld P, Bodmer M, Jick SS, et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc 2012;60:916-21
   PubMed Web of Science ®Google Scholar
• Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-8
   PubMed Web of Science ®Google Scholar
• Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:246-54
   PubMed Web of Science ®Google Scholar
• Roses AD, Saunders AM, Huang Y, et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 2007;7:10-28
   PubMed Web of Science ®Google Scholar
• Escribano L, Simon AM, Gimeno E, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010;35:1593-604
   PubMed Web of Science ®Google Scholar
• Escribano L, Simon AM, Perez-Mediavilla A, et al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009;379:406-10
   PubMed Web of Science ®Google Scholar
• Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010;30:131-46
   PubMed Web of Science ®Google Scholar
• Tzimopoulou S, Cunningham VJ, Nichols TE, et al. A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimer's Dis 2010;22:1241-56
   PubMed Web of Science ®Google Scholar
• Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011;8:592-606
   PubMed Web of Science ®Google Scholar
• Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann Pharmacother 2011;45:1416-24
   PubMed Web of Science ®Google Scholar
• Galea E, Feinstein DL, Lacombe P. Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice. Diabetologia 2006;49:2153-61
   PubMed Web of Science ®Google Scholar